Theratechnologies Inc T.TH

Question ???

[stephanedodier]

With the current burn rate, and please read the risk section on cash for the next 12 months .... How will they be able to conduct TH-1902 Phase 1 Trial (again) if FDA say GO ?

Thay cannot invest in this trial without new cash, on top of Marathon $20M.

I think we should read it this way .... no cash for TH-1902, no cash for NASH, we are looking for someone to buy us cheap by 2030 at (we hope) a minimum proce of $1,41US....

I was looking for a good news today but I cannot find any.

[SPCEO1]

My read has already been that the restart of the TH-1902 trial is a ways off. The earliest it could restart is likely late 2022 but the desire to reach cash flow positive state by eyar-end likely puts that restart off until they qualify for the third tranche of the loan or at the beginning of 2024.  I was pleased they had $33 million in cash at the end of the year. That was much better than

[palinc2000]

from the annual infomation form We are no longer conducting research and development work on TH1904, one of our other investigational PDCs. However, we continue the conduct of research and development activities on other PDCs, primarily to advance a PDC using SN38.

[Wino115]

I'd have to go through the numbers more precisely, but you had $40mil+ of RD spend  last year --cash outflow. I think they know a lot of that was one-off for last year -the IV trial, Nash spend, oncology, IM spend, water spend. Almost all of that except IM spend won't occur this year. And they will cut back oncology a huge amount and wait to see the plan. So you have something like

[Wino115]

Dubuc pretty clear the RD number will be around 2021's $28mil and overall opex will drop back to the 2021 level.  It was $93mil 2022 and 2021 was around $72mil, so the general plan is save $20mil on expenses and see revenues grow $10-15mil for a net change of $30-35mil on EBITDA.  That's pretty significant.  Give the 7% price rise for drugs already, the revenue should be at